An interventional study of Synbiotic complement and Placebo in Athlete and Sedentary Behavior, sponsored by Catholic University of Murcia. Completed at 1 site in Spain. Open to male participants aged 18 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-02.
Sponsored by Catholic University of Murcia · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Sedentary Behavior with a site in Spain — 21 open to participants now, 30 under way, none of them phase 3. Sedentary Behavior · Spain.
Among the 64 studies in Sedentary Behavior with a site in Spain, this one is the 46th largest by enrollment of the 48 interventional ones that give a count, is one of 4 that started in 2019, is one of 48 with no phase, and was the 15th registered.
1,276 studies on the registry are indexed under Sedentary Behavior; 292 are open to participants now.
Browse Sedentary Behavior studies →21 of the 64 studies in Sedentary Behavior with a site in Spain are open now. Recruiting first, the newest first:
Cuerpos Serranos S.L. · Sites in Spain
Ages 40–70 · Women only · Healthy volunteers
University of the Basque Country (UPV/EHU) · Sites in Spain
Ages 18–65
University of Vic - Central University of Catalonia · Sites in Spain, Lithuania, United Kingdom
Ages 50–100
University of Alcala · Sites in Spain
Ages 18+ · Healthy volunteers
Technical University of Madrid · Sites in Spain
Ages 40–75 · Healthy volunteers
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 184 Sedentary Behavior studies recruiting now, 77 (42%) set no upper age limit and 82 (45%) stop at 75 or younger; 30 take children under 18; 97 take healthy volunteers.
This study: 18 Years to 30 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 4 started in 2019.
This study's enrollment of 27 is below the median of 60 across 1,077 interventional studies indexed under Sedentary Behavior.
Median enrollment 120 across the 48 interventional studies, 328 across the 16 observational. Of the 25 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 64 have an industry lead sponsor. The 10 most frequent:
Catholic University of Murcia is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
Catholic University of Murcia has 1 study filed under Sedentary Behavior — fewer than ten, so there is no comparison to draw.
4 of the studies in Sedentary Behavior with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07685080Escuela Universitaria de Osuna"Effectiveness of Supervised and Unsupervised mHealth-based Exercise Interventions on Clinical Outcomes in Adults With Type 2 Diabetes and Obesity Within a Primary Care Context" | 2027-03-30 |
| NCT07809750Universidad Complutense de MadridAcute Effects of Active Breaks and Physically Active Learning in University Students | 2027-06-30 |
| NCT07103343University of Castilla-La ManchaMOVI-OLE! [Open Learning Environments] | 2027-08-31 |
| NCT06583733University of Vic - Central University of CataloniaKeep On Keep Up Bladder Health: Co-creating and Testing a Self-management Technological Solution for Ageing Well | 2027-08-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 64 studies in Sedentary Behavior with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main objective of this research was to carry out an experimental study, triple blind, on the possible immunophysiological effects of a nutritional supplement (Synbiotic, Gasteel Plus®, Heel España S.A.U.), containing a mixture of probiotic strains, such as Bifidobacterium lactis CBP-001010, Lactobacillus rhamnosus CNCM I-4036, Bifidobacterium longum ES1, as well as prebi-otic fructooligosaccharides, in both professional athletes and sedentary people. The effects on some inflammatory/immune (IL-1β, IL-10, and immunoglobulin A) and stress (epinephrine, nore-pinephrine, dopamine, serotonin, CRH, ACTH, and cortisol) biomarkers were evaluated, determined by flow cytometer and ELISA. The effects on metabolic profile and physical activity, as well as on various parameters that could affect physical and mental health, were also evaluated via the use of accelerometry and validated questionnaires.
This investigation was a triple blinded, randomized, placebo-controlled pilot study designed to identify the possible differing effects of the synbiotic Gasteel Plus® supplementation.
The participants were professional soccer players of the Second Division B of the Spanish League and sedentary students of the same sex and age range. Both study groups were randomly divided into two groups: a control group administered with placebo, and an experimental group administered with the synbiotic. Each participant was evaluated at baseline, as well as after the intervention which lasted one month. Only in the athletes group did the synbiotic intervention clearly improve objective physical activ-ity and sleep quality, as well as perceived general health, stress, and anxiety levels.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Soccer player consuming placebo sticks filled with 300 mg excipient of maltodextrin
Dietary Supplement: Placebo
Soccer players consuming a mixture of probiotic strains: Bifidobacterium lactis CBP-001010, Lactobacillus rhamno-sus CNCM I-4036, Bifidobacterium longum ES1 and fructooligosaccharides (200 mg) as a prebiotic
Dietary Supplement: Synbiotic complement
Sedentary individuals consuming placebo sticks filled with 300 mg excipient of maltodextrin
Dietary Supplement: Placebo
Sedentary individuals consuming a mixture of probiotic strains: Bifidobacterium lactis CBP-001010, Lactobacillus rhamno-sus CNCM I-4036, Bifidobacterium longum ES1 and fructooligosaccharides (200 mg) as a prebiotic
Dietary Supplement: Synbiotic complement
On two separate days, the "baseline-tests" and "final-tests" were conducted. All participants performed a series of tests, before which they had to fast. The order and schedule (8 am) of the tests was the same for the "final-test" and the same materials and procedures were used. A period of 30 consecutive days elapsed between the base-line and final tests, during which the participants had to ingest their supplement (synbiotic).
On two separate days, the "baseline-tests" and "final-tests" were conducted. All participants performed a series of tests, before which they had to fast. The order and schedule (8 am) of the tests was the same for the "final-test" and the same materials and procedures were used. A period of 30 consecutive days elapsed between the base-line and final tests, during which the participants had to ingest their supplement (placebo).
Objective determination of levels of physical activity, sedentary lifestyle and sleep quality: accelerometry
Participants wore the accelerometer held with an elastic band on the non-dominant wrist for 7 consecutive days and without interruption, except for those times of the day in which the correct operation of the device could be compromised (showers or any activity related to wa-ter). Subsequently, the files generated by the accelerometer were analyzed through a specific software called Actilife 6 (Actigraph, Pensacola, USA).
Time frame: During 7 days before the ingestion of the synbiotic or placebo
Objective determination of levels of physical activity, sedentary lifestyle and sleep quality: accelerometry
Participants wore the accelerometer held with an elastic band on the non-dominant wrist for 7 consecutive days and without interruption, except for those times of the day in which the correct operation of the device could be compromised (showers or any activity related to wa-ter). Subsequently, the files generated by the accelerometer were analyzed through a specific software called Actilife 6 (Actigraph, Pensacola, USA).
Time frame: During 7 days after the ingestion of the synbiotic or placebo
Questionnarie about general health.
SF-36 Questionnaire: Scale from 0 to 100. Higher scores mean a better outcome.
Time frame: One day before the ingestion of the synbiotic or placebo
Questionnarie about general health.
SF-36 Questionnaire: Scale from 0 to 100. Higher scores mean a better outcome.
Time frame: One day after the ingestion of the synbiotic or placebo
Questionnarie about anxiety levels (moment)
The State Anxiety Inventory (STAI): Scale from 0 to 60. Higher scores mean a worse outcome.
Time frame: One day before the ingestion of the synbiotic or placebo
Questionnarie about anxiety levels (moment)
The State Anxiety Inventory (STAI): Scale from 0 to 60. Higher scores mean a worse outcome.
Time frame: One day after the ingestion of the synbiotic or placebo
Questionnarie about anxiety levels (personality)
The Trait Anxiety Inventory (STAI): Scale from 0 to 60. Higher scores mean a worse outcome.
Time frame: One day before the ingestion of the synbiotic or placebo
Questionnarie about anxiety levels (personality)
The Trait Anxiety Inventory (STAI): Scale from 0 to 60. Higher scores mean a worse outcome.
Time frame: One day after the ingestion of the synbiotic or placebo
Questionnarie about sleep quality
Healthy Lifestyle and Personal Control Questionnaire: Scale from -1 to 10. Higher scores mean a better outcome.
Time frame: One day before the ingestion of the synbiotic or placebo
Questionnarie about sleep quality
Healthy Lifestyle and Personal Control Questionnaire: Scale from -1 to 10. Higher scores mean a better outcome.
Time frame: One day after the ingestion of the synbiotic or placebo
Questionnarie about perceived stress
The Perceived Stress Scale: Scale from 0 to 56. Higher scores mean a worse outcome.
Time frame: One day before the ingestion of the synbiotic or placebo
Questionnarie about perceived stress
The Perceived Stress Scale: Scale from 0 to 56. Higher scores mean a worse outcome.
Time frame: One day after the ingestion of the synbiotic or placebo
Questionnarie about perceived fatigue
Brief Fatigue Inventory: Scale from 0 to 40. Higher scores mean a worse outcome.
Time frame: One day before the ingestion of the synbiotic or placebo
Questionnarie about perceived fatigue
Brief Fatigue Inventory: Scale from 0 to 40. Higher scores mean a worse outcome.
Time frame: One day after the ingestion of the synbiotic or placebo
Questionnarie about perceived depression
Beck´s Depression Inventory: Scale from 0 to 63. Higher scores mean a worse outcome.
Time frame: One day before the ingestion of the synbiotic or placebo
Questionnarie about perceived depression
Beck´s Depression Inventory: Scale from 0 to 63. Higher scores mean a worse outcome.
Time frame: One day after the ingestion of the synbiotic or placebo
Determination of the pro-inflammatory cytokine IL-1β (Blood sampling)
Using the LuminexTM 200 System instrument (Luminex Corporation, Texas, USA) using the ProcartaPlex TM Multiplex Immunoassay for analysis. Measured in pg/ml.
Time frame: One day before the ingestion of the synbiotic or placebo
Determination of the pro-inflammatory cytokine IL-1β (Blood sampling)
Using the LuminexTM 200 System instrument (Luminex Corporation, Texas, USA) using the ProcartaPlex TM Multiplex Immunoassay for analysis. Measured in pg/ml.
Time frame: One day after the ingestion of the synbiotic or placebo
Determination of the anti-inflammatory cytokine IL-10 (Blood sampling)
Using the LuminexTM 200 System instrument (Luminex Corporation, Texas, USA) using the ProcartaPlex TM Multiplex Immunoassay for analysis. Measured in pg/ml.
Time frame: One day before the ingestion of the synbiotic or placebo
Determination of the anti-inflammatory cytokine IL-10 (Blood sampling)
Using the LuminexTM 200 System instrument (Luminex Corporation, Texas, USA) using the ProcartaPlex TM Multiplex Immunoassay for analysis. Measured in pg/ml.
Time frame: One day after the ingestion of the synbiotic or placebo
Determination of the stress hormones Cortisol (Blood sampling)
Analyzed by competitive inhibition enzyme immunoassays (ELISA), using The DetectX Cortisol Immunoassay Kit. Measured in µg/dl.
Time frame: One day before the ingestion of the synbiotic or placebo
Determination of the stress hormones Cortisol (Blood sampling)
Analyzed by competitive inhibition enzyme immunoassays (ELISA), using The DetectX Cortisol Immunoassay Kit. Measured in µg/dl.
Time frame: One day after the ingestion of the synbiotic or placebo
Determination of the adrenocorticotropic hormone (ACTH) (Blood sampling)
Analyzed by competitive inhibition enzyme immunoassays (ELISA), using The Human ACTH (Adrenocorticotropic Hormone) ELISA Kit (Elabscience, USA). Measured in pg/ml.
Time frame: One day before the ingestion of the synbiotic or placebo
Determination of the adrenocorticotropic hormone (ACTH) (Blood sampling)
Analyzed by competitive inhibition enzyme immunoassays (ELISA), using The Human ACTH (Adrenocorticotropic Hormone) ELISA Kit (Elabscience, USA). Measured in pg/ml.
Time frame: One day after the ingestion of the synbiotic or placebo
Determination of the corticotropin-releasing hormone (CRH) (Blood sampling)
Analyzed by competitive inhibition enzyme immunoassays (ELISA), using The Human Corticotropin Releasing Hormone (CRH) RD-CRH-Hu (Kelowna, BC, V1W 4V3, Canada) Measured in pg/ml.
Time frame: One day before the ingestion of the synbiotic or placebo
Determination of the corticotropin-releasing hormone (CRH) (Blood sampling)
Analyzed by competitive inhibition enzyme immunoassays (ELISA), using The Human Corticotropin Releasing Hormone (CRH) RD-CRH-Hu (Kelowna, BC, V1W 4V3, Canada) Measured in pg/ml.
Time frame: One day after the ingestion of the synbiotic or placebo
Determination of the stress hormones serotonin (Blood sampling)
Analyzed by competitive inhibition enzyme immunoassays (ELISA), using The General 5-Hydroxytryptamine (5-HT) RD-5-HT-Ge. Measured in ng/ml.
Time frame: One day before the ingestion of the synbiotic or placebo
Determination of the stress hormones serotonin (Blood sampling)
Analyzed by competitive inhibition enzyme immunoassays (ELISA), using The General 5-Hydroxytryptamine (5-HT) RD-5-HT-Ge. Measured in ng/ml.
Time frame: One day after the ingestion of the synbiotic or placebo
Determination of the catecholamine dopamine (Blood sampling)
Analyzed by competitive inhibition enzyme immunoassays (ELISA), using The Dopamine Research Immunoassay Measured in ng/ml.
Time frame: One day before the ingestion of the synbiotic or placebo
Determination of the catecholamine dopamine (Blood sampling)
Analyzed by competitive inhibition enzyme immunoassays (ELISA), using The Dopamine Research Immunoassay Measured in ng/ml.
Time frame: One day after the ingestion of the synbiotic or placebo
Determination of the catecholamine epinephrine (Blood sampling)
Analyzed by competitive inhibition enzyme immunoassays (ELISA), using The General Epinephrine (EPI) RD-EPI-Ge-96T. Measured in pg/ml.
Time frame: One day before the ingestion of the synbiotic or placebo
Determination of the catecholamine epinephrine (Blood sampling)
Analyzed by competitive inhibition enzyme immunoassays (ELISA), using The General Epinephrine (EPI) RD-EPI-Ge-96T. Measured in pg/ml.
Time frame: One day after the ingestion of the synbiotic or placebo
Determination of the catecholamine norepinephrine (Blood sampling)
Analyzed by competitive inhibition enzyme immunoassays (ELISA), using The General Noradrenaline (NE) RD-NE-Ge-96T. Measured in pg/ml.
Time frame: One day before the ingestion of the synbiotic or placebo
Determination of the catecholamine norepinephrine (Blood sampling)
Analyzed by competitive inhibition enzyme immunoassays (ELISA), using The General Noradrenaline (NE) RD-NE-Ge-96T. Measured in pg/ml.
Time frame: One day after the ingestion of the synbiotic or placebo
Determination of the immunoglobulin A (Saliva sampling)
Analyzed by indirect enzyme immunoassay kit through the Salivary Secretory IgA Kit (Salimetrics LLC, USA). The procedures followed the instructions of the manufacturers, and the findings were measured using an ELISA auto analyzer to quantify color intensity (Sunrise, Tecan, Männendorf, Switzerland). Measured in µg/ml
Time frame: One day before the ingestion of the synbiotic or placebo
Determination of the immunoglobulin A (Saliva sampling)
Analyzed by indirect enzyme immunoassay kit through the Salivary Secretory IgA Kit (Salimetrics LLC, USA). The procedures followed the instructions of the manufacturers, and the findings were measured using an ELISA auto analyzer to quantify color intensity (Sunrise, Tecan, Männendorf, Switzerland). Measured in µg/ml
Time frame: One day after the ingestion of the synbiotic or placebo
Determination of glucose levels (metabolic profile)
The determinations for obtaining the glycemic profile were carried out through standard techniques with the automatic analyzer of clinical chemistry BA 400 (BioSystems) in the SYNLAB laboratories (Diagnosticos Globales S.A.U., Badajoz, Spain). Measured in mg/dl
Time frame: One day before the ingestion of the synbiotic or placebo
Determination of glucose levels (metabolic profile)
The determinations for obtaining the glycemic profile were carried out through standard techniques with the automatic analyzer of clinical chemistry BA 400 (BioSystems) in the SYNLAB laboratories (Diagnosticos Globales S.A.U., Badajoz, Spain). Measured in mg/dl
Time frame: One day after the ingestion of the synbiotic or placebo
Determination of total cholesterol levels (metabolic profile)
The determinations for obtaining the lipid profile were carried out through standard techniques with the automatic analyzer of clinical chemistry BA 400 (BioSystems) in the SYNLAB laboratories (Diagnosticos Globales S.A.U., Badajoz, Spain). Measured in mg/dl
Time frame: One day before the ingestion of the synbiotic or placebo
Determination of total cholesterol levels (metabolic profile)
The determinations for obtaining the lipid profile were carried out through standard techniques with the automatic analyzer of clinical chemistry BA 400 (BioSystems) in the SYNLAB laboratories (Diagnosticos Globales S.A.U., Badajoz, Spain). Measured in mg/dl
Time frame: One day after the ingestion of the synbiotic or placebo
Determination of the triglycerides levels (metabolic profile)
The determinations for obtaining the lipid profile were carried out through standard techniques with the automatic analyzer of clinical chemistry BA 400 (BioSystems) in the SYNLAB laboratories (Diagnosticos Globales S.A.U., Badajoz, Spain). Measured in mg/dl
Time frame: One day before the ingestion of the synbiotic or placebo
Determination of the triglycerides levels (metabolic profile)
The determinations for obtaining the lipid profile were carried out through standard techniques with the automatic analyzer of clinical chemistry BA 400 (BioSystems) in the SYNLAB laboratories (Diagnosticos Globales S.A.U., Badajoz, Spain). Measured in mg/dl
Time frame: One day after the ingestion of the synbiotic or placebo
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The raw data supporting the conclusions of this intervention will be made available by the investigators, without undue reservation, to any qualified researcher
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: The data will be always available upon reasonable request
Access criteria: The data that support the findings of this study are available via email from the corresponding author upon reasonable request.
Ran from May 2019 to primary completion in Jun 2019, 1 month.
Of 736 non-industry interventional studies with no phase under Sedentary Behavior, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 30. This study's 1 month is below that.
Counting every sponsor, half of 744 studies reached it within 14 months; a quarter within 6 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Catholic University of Murcia